
Opinion|Videos|January 20, 2025
Patient Selection for Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
5 Novel Mechanisms Reshaping Atopic Dermatitis Treatment and the Phase 2-3 Clinical Trials That Support Them
2
CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial
3
Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk
4
Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease
5































































































































































































































































































